SCHEMBL5544169

SCHEMBL5544169

COc1ccccc1NC1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 2/20 0.51
▸ MAPT P10636 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ TSHR P16473 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ DRD3 P35462 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ EGFR P00533 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TYR P14679 1/20 0.41
▸ PABPC1 P11940 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ EHMT2 Q96KQ7 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537861 0.89 L3MBTL1 (0.53) DRD2MAPTNPC1RAB9ANPSR1
SCHEMBL5544175 0.87 TYR (0.53) DRD2MAPTNPC1RAB9ATSHR
SCHEMBL5537487 0.84 DDB1 (0.46) DRD2EGFRGAA
SCHEMBL5538936 0.82 MEN1 (0.44) MAPTNPC1RAB9ANPSR1KDM4E
SCHEMBL5539021 0.82 SCD (0.37) DRD2MAPTTSHRNPSR1KDM4E
SCHEMBL5535582 0.80 GAA (0.53) MAPTNPC1RAB9ATSHRNPSR1
SCHEMBL5536338 0.80 KMT2A (0.49) MAPTKDM4EALDH1A1GAALMNA
SCHEMBL11797086 0.80 MAPT (0.50) DRD2MAPTNPC1RAB9ATSHR
SCHEMBL5544117 0.78 EHMT2 (0.44) MAPTNPC1TSHRNPSR1KDM4E
SCHEMBL1645759 0.78 DRD2 (0.52) DRD2MAPTNPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DRD2 542/4885MAPT 4117/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback